Targeting PI3K/mTOR signaling in cancer
The phosphatidylinositol 3-kinase (PI3K)/mTOR pathway integrates signals from growth factors with nutrient signals and other conditions and controls multiple cell responses, including proliferation, survival and metabolism. Deregulation of the PI3K pathway has been extensively investigated in connec...
Պահպանված է:
| Հիմնական հեղինակ: | |
|---|---|
| Ձևաչափ: | Online |
| Լեզու: | անգլերեն |
| Հրապարակվել է: |
Frontiers Media SA
2021
|
| Խորագրեր: | |
| Առցանց հասանելիություն: | 17655 |
| Ցուցիչներ: |
Չկան պիտակներ, Եղեք առաջինը, ով նշում է այս գրառումը!
|
| _version_ | 1869517399179395072 |
|---|---|
| author | Alexandre Arcaro |
| author_browse | Alexandre Arcaro |
| author_facet | Alexandre Arcaro |
| author_sort | Alexandre Arcaro |
| collection | Directory of Open Access Books |
| description | The phosphatidylinositol 3-kinase (PI3K)/mTOR pathway integrates signals from growth factors with nutrient signals and other conditions and controls multiple cell responses, including proliferation, survival and metabolism. Deregulation of the PI3K pathway has been extensively investigated in connection to cancer. Somatic or inherited mutations frequently occur in tumor suppressor genes (PTEN, TSC1/2, LKB1) and oncogenes (PIK3CA, PIK3R1, AKT) in the PI3K/mTOR pathway. The fact that the PI3K/mTOR pathway is deregulated in a large number of human malignancies, and its importance for different cellular responses, makes it an attractive drug target. Pharmacological PI3K inhibitors have played a very important role in studying cellular responses involving these enzymes. Currently, a wide range of selective PI3K inhibitors have been tested in preclinical studies and some have entered clinical trials in oncology. Rapamycin and its analogs targeting mTOR are effective in many preclinical cancer models. Although rapalogs are approved for the treatment of some cancers, their efficacy in clinical trials remains the subject of debate. Due to the complexity of the PI3K/mTOR signaling pathway, developing an effective anti-cancer therapy remains a challenge. The biggest challenge in curing cancer patients with various signaling pathway abnormalities is to target multiple components of different signal transduction pathways with mechanism-based combinatorial treatments. |
| format | Online |
| id | doab-20.500.12854ir-60490 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2021 |
| publishDateRange | 2021 |
| publishDateSort | 2021 |
| publisher | Frontiers Media SA |
| publisherStr | Frontiers Media SA |
| record_format | ojs |
| spelling | doab-20.500.12854ir-604902024-03-30T23:22:05Z Targeting PI3K/mTOR signaling in cancer Alexandre Arcaro R5-920 QH301-705.5 RC254-282 Q1-390 Phosphoinositide 3-kinase mTOR clinical trials Akt Cancer thema EDItEUR::M Medicine and Nursing The phosphatidylinositol 3-kinase (PI3K)/mTOR pathway integrates signals from growth factors with nutrient signals and other conditions and controls multiple cell responses, including proliferation, survival and metabolism. Deregulation of the PI3K pathway has been extensively investigated in connection to cancer. Somatic or inherited mutations frequently occur in tumor suppressor genes (PTEN, TSC1/2, LKB1) and oncogenes (PIK3CA, PIK3R1, AKT) in the PI3K/mTOR pathway. The fact that the PI3K/mTOR pathway is deregulated in a large number of human malignancies, and its importance for different cellular responses, makes it an attractive drug target. Pharmacological PI3K inhibitors have played a very important role in studying cellular responses involving these enzymes. Currently, a wide range of selective PI3K inhibitors have been tested in preclinical studies and some have entered clinical trials in oncology. Rapamycin and its analogs targeting mTOR are effective in many preclinical cancer models. Although rapalogs are approved for the treatment of some cancers, their efficacy in clinical trials remains the subject of debate. Due to the complexity of the PI3K/mTOR signaling pathway, developing an effective anti-cancer therapy remains a challenge. The biggest challenge in curing cancer patients with various signaling pathway abnormalities is to target multiple components of different signal transduction pathways with mechanism-based combinatorial treatments. 2021-02-12T05:15:03Z 2021-02-12T05:15:03Z 2015-11-16 15:44:59 2014 book 17655 16648714 9782889192441 https://directory.doabooks.org/handle/20.500.12854/60490 eng Frontiers Research Topics image/jpeg Attribution 4.0 International http://www.frontiersin.org/books/Targeting_PI3K_mTOR_signaling_in_cancer/293 http://journal.frontiersin.org/researchtopic/661/targeting-pi3kmtor-signaling-in-cancer Frontiers Media SA 10.3389/978-2-88919-244-1 10.3389/978-2-88919-244-1 bf5ce210-e72e-4860-ba9b-c305640ff3ae 9782889192441 93 open access |
| spellingShingle | R5-920 QH301-705.5 RC254-282 Q1-390 Phosphoinositide 3-kinase mTOR clinical trials Akt Cancer thema EDItEUR::M Medicine and Nursing Alexandre Arcaro Targeting PI3K/mTOR signaling in cancer |
| title | Targeting PI3K/mTOR signaling in cancer |
| title_full | Targeting PI3K/mTOR signaling in cancer |
| title_fullStr | Targeting PI3K/mTOR signaling in cancer |
| title_full_unstemmed | Targeting PI3K/mTOR signaling in cancer |
| title_short | Targeting PI3K/mTOR signaling in cancer |
| title_sort | targeting pi3k mtor signaling in cancer |
| topic | R5-920 QH301-705.5 RC254-282 Q1-390 Phosphoinositide 3-kinase mTOR clinical trials Akt Cancer thema EDItEUR::M Medicine and Nursing |
| topic_facet | R5-920 QH301-705.5 RC254-282 Q1-390 Phosphoinositide 3-kinase mTOR clinical trials Akt Cancer thema EDItEUR::M Medicine and Nursing |
| url | 17655 |
| work_keys_str_mv | AT alexandrearcaro targetingpi3kmtorsignalingincancer |